https://scholars.lib.ntu.edu.tw/handle/123456789/630198
Title: | Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine | Authors: | Li, Chia-Jung Jiang, Chung-Lin TAI-LING CHAO Lin, Shiau-Yu Tsai, Ya-Min Chao, Chong-Syun Su, Yu-Ting Chen, Chun-Jen SUI-YUAN CHANG FU-JUNG LIN SHIH-CHUNG CHANG |
Keywords: | Neutralizing antibody; Obesity; Receptor-binding domain (RBD); SARS-CoV-2; Spike protein; Vaccine | Issue Date: | 29-Mar-2023 | Publisher: | Springer Science and Business Media Deutschland GmbH | Start page/Pages: | 1-13 | Source: | Applied microbiology and biotechnology | Abstract: | Vaccination is considered to be the most effective countermeasure to prevent and combat the global health threats of COVID-19. People with obesity are at a greater risk of hospitalization, life-threatening illness, and adverse outcomes after having COVID-19. Therefore, a safe and effective COVID-19 vaccine for obese individuals is urgently needed. In the study, the vaccine composed of the ISA 51 adjuvant and the SARS-CoV-2 spike (S) receptor-binding domain (RBD) in conjugation with the human IgG1 Fc fragment (named as ISA 51-adjuvanted RBD-Fc vaccine) was developed and inoculated in the regular chow diet (RCD) lean mice and the high-fat diet (HFD)-induced obese mice. The S protein-specific IgG titers were largely induced in an increasing manner along with three doses of ISA 51-adjuvanted RBD-Fc vaccine without causing any harmful side effect. In the HFD mice, the S protein-specific IgG titers can be quickly observed 2 weeks post the first inoculation. The antisera elicited by the ISA 51-adjuvanted RBD-Fc vaccine in the RCD and HFD mice exhibited potent SARS-CoV-2 neutralizing activities in the plaque reduction neutralization test (PRNT) assays and showed similar specificity for recognizing the key residues in the RBD which were involved in interacting with angiotensin-converting enzyme 2 (ACE2) receptor. The immune efficacy of the ISA 51-adjuvanted RBD-Fc vaccine in the HFD mice can be sustainably maintained with the PRNT50 values of 1.80-1.91×10-3 for at least 8 weeks post the third inoculation. Collectively, the RBD-Fc-based immunogen and the ISA 51-adjuvanted formulation can be developed as an effective COVID-19 vaccine for obese individuals. KEY POINTS: • The ISA 51-adjuvanted RBD-Fc vaccine can induce potent SARS-CoV-2 neutralizing antibodies in the obese mouse • The antibodies elicited by the ISA 51-adjuvanted RBD-Fc vaccine can bind to the key RBD residues involved in interacting with ACE2 • The immune efficacy of the ISA 51-adjuvanted RBD-Fc vaccine can be sustainably maintained for at least 8 weeks post the third inoculation. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630198 | ISSN: | 01757598 | DOI: | 10.1007/s00253-023-12490-8 |
Appears in Collections: | 生化科技學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.